Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44 million, which includes ...

ZUNVEYL represents a significant advancement in Alzheimer’s care and it is only the second oral AD treatment to be approved in more than a decade. Alpha Cognition’s leadership team will ...

Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.

It was a landmark year for medical advancements in 2024, bringing a wave of innovative treatments that promise to reshape ...

About ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the ...

Zunveyl is a next-generation acetylcholinesterase inhibitor approved in the U.S. for mild-to-moderate Alzheimer's disease. The deal value is $44 million, including $6 million in total upfront ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better ...